Bristol-Myers establishes clinical trial collaboration in blood cancers

• Bristol-Myers Squibb (NYSE:BMY), Pharmacyclics (NASDAQ:PCYC) and Janssen Research & Development (NYSE:JNJ) enter into a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of BMY's Opdivo (nivolumab) in combination with Imbruvica (ibrutinib) as treatment for patients with non-Hodgkin lymphoma, diffuse larger B-cell lymphoma, follicular lymphoma and chronic lymphocytic leukemia.
• The clinical study will be conducted by Janssen.
• No additional details about the collaboration are disclosed.